Orders from 465 AED Free delivery from 965 AED Ready for pickup dead drop: collect in 5 min

Substances · Arylcyclohexylamines

Ketamine

C13H16ClNO CAS 6740-88-1 Analytical reference material — not for human consumption
Preferred name
Ketamine
IUPAC name
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
Parent CAS number (reference)
6740-88-1
Molecular formula
C13H16ClNO
Molecular weight
237.72 g/mol
InChIKey
YQEZLKZALYSWHR-UHFFFAOYSA-N
PubChem
CID 3821
Source
PubChem
Verified synonyms & catalog abbreviations
Ketamina CI-581 2-Chloro-2'-oxo-PCM

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

Ketamine

Short-Acting Reference NMDA Receptor Antagonist Arylcyclohexylamine
Verified PubChem & CAS Identity C13H16ClNO · CAS 6740-88-1 · CID 3821
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 237.72 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

NMDA Uncompetitive Channel Blockade Primary
SERT / DAT Monoamine Reuptake Tone Low

Uncompetitive NMDA receptor channel blocker (Ki = 500 nM) with rapid distribution and short elimination (T1/2 ~2.5 h).

Biotransformation & Active Metabolites

Rapid hepatic CYP3A4/2B6 N-demethylation to norketamine and hydroxynorketamine.

Temporal Pharmacokinetics

Short-Acting Reference NMDA Receptor Antagonist — Shortest-acting dissociative benchmark; lower oral bioavailability than 2-FDCK; chronic frequent exposure carries documented ketamine cystitis / urological bladder toxicity.

  1. Onset 15–30 min
  2. Peak Window 30–60 min
  3. Total Window 1–2.5 h
  4. Residual / Half-Life 1–3 h mild ataxia

Shortest-acting dissociative benchmark; lower oral bioavailability than 2-FDCK; chronic frequent exposure carries documented ketamine cystitis / urological bladder toxicity.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
15–30 mg
Cognitive & Sensory

Subtle threshold receptor activity (Short-Acting Reference NMDA Receptor Antagonist).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
30–75 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
75–150 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
150–250 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
300+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Alcohol, Opioids (O-DSMT), Benzodiazepines, and GHB/GBL

Severe ataxia, unconsciousness, respiratory depression, and fatal vomiting aspiration.

Elevated Hazard — Avoid

Strong Stimulants (Cathinones, Cocaine, Amphetamines)

Compounds hypertension, tachycardia, manic disorientation, and psychotic episodes.

Caution / Receptor Attenuation

Cannabis & Psychedelics

Dramatically intensifies dissociation, confusion, and sensory immersion.

Structural Isomer & Sibling Comparison

Shortest-acting dissociative benchmark; lower oral bioavailability than 2-FDCK; chronic frequent exposure carries documented ketamine cystitis / urological bladder toxicity.

Physicochemical Stability & Storage

Form: White to off-white crystalline powder or fine crystals. · Soluble in water, ethanol, and saline.

Chemically stable when kept dry, sealed, and protected from light at room temperature.

Cross-Tolerance & Dependence Profile

Slowly decaying NMDA cross-tolerance shared across all arylcyclohexylamines (halves in ~3–7 days, full baseline 2+ weeks). Chronic frequent exposure carries documented urological/bladder epithelial toxicity.

Comprehensive Analytical & Toxicological Monograph

Ketamine (2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; CAS 6740-88-1, PubChem CID 3821) is a arylcyclohexylamine reference compound (C13H16ClNO, 237.72 g/mol) classified pharmacologically as a Short-Acting Reference NMDA Receptor Antagonist. Uncompetitive NMDA receptor channel blocker (Ki = 500 nM) with rapid distribution and short elimination (T1/2 ~2.5 h). Rapid hepatic CYP3A4/2B6 N-demethylation to norketamine and hydroxynorketamine. In published observational and toxicological literature, threshold response is noted at 15–30 mg, light range at 30–75 mg, common reference range at 75–150 mg, strong intensity at 150–250 mg, and heavy/adverse territory at 300+ mg, with an onset of 15–30 min, peak window of 30–60 min, and total duration of 1–2.5 h (1–3 h mild ataxia). Shortest-acting dissociative benchmark; lower oral bioavailability than 2-FDCK; chronic frequent exposure carries documented ketamine cystitis / urological bladder toxicity. Critical contraindications include Alcohol, Opioids (O-DSMT), Benzodiazepines, and GHB/GBL.

Chemical Architecture & Structural Profile

Ketamine (2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one) is a reference compound belonging to the Arylcyclohexylamines class, characterized by the molecular formula C13H16ClNO and a molar mass of 237.72 g/mol. The parent molecule is indexed under CAS registry number 6740-88-1 and in the NCBI PubChem database as CID 3821 (Standard InChIKey: YQEZLKZALYSWHR-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Ketamine is indexed within the Arylcyclohexylamines structural group. Arylcyclohexylamine derivative; toxicological literature highlights severe hazard interactions when combined with central nervous system depressants (alcohol, GHB/GBL, opioids, benzodiazepines). Dependence liability (PsychonautWiki): moderate to high abuse potential and produces psychological dependence with chronic use. Documented cross-tolerance class: dissociative. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

High-risk / Dangerous combinations

Uncertain combinations (caution advised)